Silicon Valley startup InSilixa roped in $13M in financing to develop its innovative molecular diagnostic tests for drug-resistant bacteria and infections.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
As concern mounts over the deadly Ebola epidemic, French scientists are developing a diagnostic tool that works similar to a home pregnancy test and can quickly identify the virus through a tiny fluid sample. Read more >>
Amid efforts to counter the deadly Ebola outbreak, researchers and companies are homing in on rapid mobile tests as a more effective way to prevent the disease's spread.
QuantuMDx is teaming up with a Swiss nonprofit organization to develop its handheld test for tuberculosis, building momentum for a full commercial rollout of its innovative diagnostic tool.
Molecular diagnostics developer Nanosphere reeled in $18.4 million in a stock sale with the proceeds slotted to be used for general corporate purposes and working capital.
Researchers at the University of Wisconsin-Madison have come up with an implantable sensor so thin that scientists studying the brain can see through it using a wide range of imaging technologies.
BioFire, a subsidiary of French diagnostics outfit bioMérieux, was granted emergency authorization from the FDA for two of its Ebola tests.
From Our Sister Sites
U.K. researchers have hit upon a drug combination that appears to combat lung cancer by triggering self-destruction in tumor cells.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.